A pan-cancer analysis found that higher WHO grade and stage were substantially correlated with unbalanced TCRG expression, and shorter survival, increased tumor mutational burden, and activation of tumor-related pathways in patients [38]. The gene discussed is TRGC1; the disease is cancer.